ArticleAACE endocrinology and diabetes
A Case of Acromegaly With Parasellar Meningioma With Oculomotor Palsy Responding to and Maintained With Oral Octreotide Therapy.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Meningiomas are the most frequently occurring primary central nervous system tumors. Recommended treatment options for large, growing, or symptomatic meningiomas typically involve surgical removal (when possible) and/or radiation therapy. There is no sufficient evidence of effective systemic therapies for recurrent meningioma. Case Report: A 65-year-old female, after 20 years of stability with acromegaly, presented to the emergency department with a sudden onset of blurring of vision and was found to have severe left oculomotor nerve palsy. Brain magnetic resonance imaging showed an 11 × 9 × 9 mm enhancing homogenous dural-based mass within the posterior part of the left cavernous sinus and posterior clinoid process, displacing the left oculomotor nerve and abutting the internal carotid artery. Treatment with surgery or radiation was not considered as feasible due to the location of the mass and the patient's comorbidities at that time. Given that imaging showed a dural-based mass suggestive of meningioma, and acromegaly recurrence could not be excluded due to IGF-1 being at the upper end of normal, oral octreotide was increased from 40 mg to 80 mg daily, targeting both possible etiologies, with particular rationale based on known somatostatin receptor expression in meningioma. Discussion: Increased octreotide dosage in a patient with acromegaly effectively managed ocular motor palsy and reduced the size of meningioma. Conclusion: Current findings from our case may provide evidence for the potential use of somatostatin analogs in treating acromegaly patients diagnosed with meningiomas, particularly those cases that cannot be surgically removed, to alleviate certain neurological symptoms associated with the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.